According to filings with the U.S. Securities and Exchange Commission, Arkea Bio Corp. is raising up to $12,000,017.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Arkea Bio Corp.
ArkeaBio is a global agricultural bioscience company developing a safe, cost-effective vaccine to reduce methane emissions from cattle all over the world. We are the first to successfully demonstrate a proof-of-concept vaccine. Its the safest, most cost-effective solution for reducing greenhouse gas emissions in agriculture, and its the only one that can be quickly and sustainably scaled to reach all the worlds cattle. Its a singular, scalable solution that delivers value to farmers, brands, consumers and our climate.

To learn more about Arkea Bio Corp., visit https://www.arkeabio.com/
Arkea Bio Corp. Linkedin Page: https://www.linkedin.com/company/arkeabio/

Contact:
Frank Wooten, President and Chief Executive Officer
833-275-3224

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.